The publication of this infographic was supported by AstraZeneca. This content is intended for US Healthcare Professionals only.
This infographic presents three-year follow-up data from the TOPAZ-1 trial; the first global Phase III study to evaluate an immuno-oncology-based regimen in the first-line setting for advanced biliary tract cancers. It summarizes overall survival outcomes, safety findings, and additional analyses conducted across multiple patient subgroups.
Key Insights:
- TOPAZ-1 is the first advancement in the first-line setting for advanced biliary tract cancers in over 10 years.
- Three-year survival data showed 2× more patients were estimated to be alive in the durvalumab arm vs the placebo arm (14.6% vs 6.9%).
- Additional analyses support the use of durvalumab plus gemcitabine and cisplatin in a broad population, irrespective of subgroup, mutation status, or antibiotic use.
